
Zdenek Racil

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8861762/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
2	lsavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infectious Diseases, The, 2016, 16, 828-837.	9.1	528
3	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
4	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. Journal of Antimicrobial Chemotherapy, 2018, 73, 3221-3230.	3.0	186
5	Utility of voriconazole therapeutic drug monitoring: a meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 1786-1799.	3.0	148
6	Difficulties in using 1,3-β-d-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies – high frequency of false-positive results and their analysis. Journal of Medical Microbiology, 2010, 59, 1016-1022.	1.8	101
7	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia, 2018, 32, 1609-1620.	7.2	80
8	Invasive infections due to <i>Saprochaete</i> and <i>Geotrichum</i> species: Report of 23 cases from the FungiScope Registry. Mycoses, 2017, 60, 273-279.	4.0	78
9	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. Journal of Clinical Oncology, 2019, 37, 2632-2642.	1.6	77
10	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood, 2022, 139, 1588-1592.	1.4	70
11	Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica, 2013, 98, e124-e126.	3.5	64
12	Rapid Detection and Identification of Mucormycetes in Bronchoalveolar Lavage Samples from Immunocompromised Patients with Pulmonary Infiltrates by Use of High-Resolution Melt Analysis. Journal of Clinical Microbiology, 2014, 52, 2824-2828.	3.9	62
13	Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses, 2012, 55, 483-492.	4.0	50
14	FungiScope [™] —Global Emerging Fungal Infection Registry. Mycoses, 2017, 60, 508-516.	4.0	47
15	Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases—the role of factors affecting assay performance. International Journal of Infectious Diseases, 2011, 15, e874-e881.	3.3	44
16	JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia, 2019, 33, 995-1010.	7.2	43
17	Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget, 2016, 7, 33016-33024.	1.8	31
18	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). Journal of Antimicrobial Chemotherapy, 2019, 74, 3315-3327.	3.0	30

ZDENEK RACIL

#	Article	IF	CITATIONS
19	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica, 2020, 105, e228-e231.	3.5	29
20	Rapid detection of fungal pathogens in bronchoalveolar lavage samples using panfungal PCR combined with high resolution melting analysis. Medical Mycology, 2016, 54, 714-724.	0.7	27
21	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematology,the, 2022, 9, e361-e373.	4.6	25
22	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Advances, 2021, 5, 3279-3289.	5.2	21
23	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeⓇ—Global Registry for Emerging Fungal Infections. Journal of Infection, 2020, 81, 802-815.	3.3	20
24	Reactivity of the 1,3â€Î²â€Dâ€glucan assay during bacteraemia: limited evidence from a prospective study. Mycoses, 2013, 56, 101-104.	4.0	18
25	Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005–2009. International Journal of Infectious Diseases, 2013, 17, e101-e109.	3.3	18
26	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. Journal of Hematology and Oncology, 2022, 15, 60.	17.0	17
27	Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin. PLoS ONE, 2018, 13, e0204290.	2.5	15
28	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica, 2020, 105, 161-169.	3.5	15
29	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. British Journal of Haematology, 2021, 192, 832-842.	2.5	15
30	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 2023, 108, 22-33.	3.5	15
31	Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica, 2022, 107, 836-843.	3.5	14
32	The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. International Journal of Hematology, 2011, 94, 303-306.	1.6	13
33	Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. American Journal of Hematology, 2018, 93, E342-E345.	4.1	13
34	The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. Archives of Medical Science, 2018, 14, 1416-1423.	0.9	12
35	Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR. Journal of Clinical Virology, 2014, 61, 270-274.	3.1	9
36	Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. British Journal of Haematology, 2019, 186, 300-310.	2.5	9

ZDENEK RACIL

#	Article	IF	CITATIONS
37	Validation of Minim typing for fast and accurate discrimination of extended-spectrum, beta-lactamase-producing Klebsiella pneumoniae isolates in tertiary care hospital. Diagnostic Microbiology and Infectious Disease, 2016, 86, 44-49.	1.8	7
38	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers, 2021, 13, 2095.	3.7	7
39	The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN. Cancers, 2021, 13, 4210.	3.7	7
40	Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. Leukemia and Lymphoma, 2013, 54, 1042-1047.	1.3	5
41	No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. Hematological Oncology, 2014, 32, 87-93.	1.7	5
42	The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1239-1251.	2.5	5
43	Clonal hierarchy of main molecular lesions in acute myeloid leukaemia. British Journal of Haematology, 2020, 190, 562-572.	2.5	5
44	Novel Illuminaâ€based next generation sequencing approach with oneâ€round amplification provides early and reliable detection of BCRâ€ABL1 kinase domain mutations in chronic myeloid leukemia. British Journal of Haematology, 2020, 189, 469-474.	2.5	5
45	BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML. Blood, 2018, 132, 1722-1722.	1.4	5
46	Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study. Leukemia and Lymphoma, 2020, 61, 494-496.	1.3	4
47	Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. American Journal of Hematology, 2012, 87, 211-213.	4.1	3
48	Serological Approaches. Methods in Molecular Biology, 2017, 1508, 209-221.	0.9	3
49	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. Leukemia, 2017, ,	7.2	3
50	Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 106-113.	0.4	2
51	Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early followâ€up. British Journal of Haematology, 2021, 194, 604-612.	2.5	2
52	Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing. Molecular Diagnosis and Therapy, 2012, 16, 163-166.	3.8	1
53	Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays. Practical Laboratory Medicine, 2021, 25, e00210.	1.3	1
54	Clinical and laboratory features of leukemias at the time of diagnosis: An analysis of 1,004 consecutive patients. American Journal of Hematology, 2011, 86, 800-803.	4.1	0

ZDENEK RACIL

#	Article	IF	CITATIONS
55	Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry. Analytical Letters, 2014, 47, 944-957.	1.8	Ο
56	Title is missing!. , 2019, 14, e0221187.		0
57	Title is missing!. , 2019, 14, e0221187.		0
58	Title is missing!. , 2019, 14, e0221187.		0
59	Title is missing!. , 2019, 14, e0221187.		0
60	Title is missing!. , 2019, 14, e0221187.		0
61	Title is missing!. , 2019, 14, e0221187.		Ο